Updated analysis on polypharmacy and mortality from the ESTHER study
- 112 Downloads
In the August 2017 issue, our group published the article “Polypharmacy and mortality: new insights from a large cohort of older adults by detection of effect modification by multi-morbidity and comprehensive correction of confounding by indication” . The most important limitation of the analyses in this article was the low number of 87 events of non-cancer mortality during a mean follow-up time of 4.4 years from the German, population-based ESTHER cohort. We now extended the mortality follow-up and would like to present the updated results. We again used the study sample of 2,687 men and women with medication data collected via the “brown-bag method” 2008–2010 , who were on average 70 years old.
This study was funded by the Federal Ministry of Education and Research (Berlin, Germany) [Grant number 01GY1320A].
Compliance with ethical standards
The ESTHER study was approved by the ethics committees of the Medical Faculty of the University of Heidelberg and the Medical Association of Saarland and is being conducted in accordance with the declaration of Helsinki.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Schöttker B, Saum KU, Muhlack DC, Hoppe LK, Holleczek B, Brenner H (2017) Polypharmacy and mortality: new insights from a large cohort of older adults by detection of effect modification by multi-morbidity and comprehensive correction of confounding by indication. Eur J Clin Pharmacol 73:1041–1048CrossRefPubMedGoogle Scholar